We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era.
- Authors
Huang, Cheng; Tang, Tian-Lan; Qiu, Yan-Yan; Lin, Yu-Ping; Chen, Si-Lin; Zhao, Rui-Zhi; Shi, Gui-Qing; Liao, Si-Qin; Chen, Jin-Hua; Fu, Hai-Ying; Liu, Jian-Zhi; Xu, Ben-Hua; Liu, Ting-Bo; Yang, Yong
- Abstract
Background: Radiotherapy (RT) is an effective and available local treatment for patients with refractory or relapsed (R/R) aggressive B-cell lymphomas. However, the value of hypofractionated RT in this setting has not been confirmed. Methods: We retrospectively analyzed patients with R/R aggressive B-cell lymphoma who received hypofractionated RT between January 2020 and August 2022 at a single institution. The objective response rate (ORR), overall survival (OS), progression-free survival (PFS) and acute side effects were analyzed. Results: A total of 30 patients were included. The median dose for residual disease was 36 Gy, at a dose per fraction of 2.3–5 Gy. After RT, the ORR and complete response (CR) rates were 90% and 80%, respectively. With a median follow-up of 10 months (range, 2–27 months), 10 patients (33.3%) experienced disease progression and three died. The 1-year OS and PFS rates for all patients were 81.8% and 66.3%, respectively. The majority (8/10) of post-RT progressions involved out-of-field relapses. Patients with relapsed diseases, no response to systemic therapy, multiple lesions at the time of RT, and no response to RT were associated with out-of-field relapses. PFS was associated with response to RT (P = 0.001) and numbers of residual sites (P < 0.001). No serious non-hematological adverse effects (≥ grade 3) associated with RT were reported. Conclusion: These data suggest that hypofractionated RT was effective and tolerable for patients with R/R aggressive B-cell lymphoma, especially for those that exhibited localized residual disease.
- Subjects
RITUXIMAB; LYMPHOMAS; RADIOTHERAPY; DISEASE relapse
- Publication
BMC Cancer, 2024, Vol 24, Issue 1, p1
- ISSN
1471-2407
- Publication type
Article
- DOI
10.1186/s12885-024-11837-2